In interventional medical devices, Signal Advance Technology could potentially reduce response delays and improve performance. Improved performance translates directly to increased value, providing a significant opportunity for revenue generation.

“A new report by Visiongain, a London-based business information provider predicts the global cardiac rhythm management market to be worth $27.8bn by 2021. The market generated $14.6bn in 2010.” [1]

This represents $13.2bn projected growth in revenues over ten years. Cardiac rhythm management includes cardiac pacing, implantable defibrillators, cardiac resynchronization and resynchronization therapy defibrillators.

“The global market for neurostimulation devices market was valued at about $1.85 billion in the year 2009. It is expected to reach a size of $4.9 billion by 2016 with a Compound Annual Growth Rate (CAGR) of 15% from 2009 to 2016.” [2]

The neurostimulation device market includes spinal cord, deep brain, vagus nerve, sacral nerve and gastric electrical stimulation. These devices are used in the treatment and management of depression, dystonia, epilepsy, essential tremors, gastro-paresis disorders, incontinence, obsessive compulsive disorder (OCD), pain and Parkinson’s disease.

Major suppliers in the CRM and neurostimulation markets include Bionet, Boston Scientific, GE Healthcare, Guidant, Johnson & Johnson, Medtronic, Smith & Nephew, St. Jude Medical, Stryker, WL Gore, and Zimmer.

The following, excerpted from an independent patent valuation, refers exclusively to the cardiac rhythm management and neurostimulation markets:

Market: The addressable market for SIGNAL ADVANCE totals approximately $3B in 20 years time, to be penetrated to levels of ~4% with slow initial impact. SIGNAL ADVANCE will compete based on superior technology and performance across a range of products.

Additional medical applications, in which SAT could improve performance, include neurofeedback therapy, neuroprosthetics, neural/man-machine interfaces, physiologically gated imaging and radio-therapy as well as real-time artifact detection/rejection for a broad range of physiological signals. For these applications, improved performance translates directly to increased value and this may provide SAI the greatest opportunity to maximize revenue generation. Further, for a number of these medical applications, SA Technology would be adjunctive – improving performance without changing the function of the device. As such, the improved devices and processes would likely be subject to FDA 510K or hybrid 510K approvals rather than the more expensive and time-consuming Pre-Market Approval process.
[1] According to Cardiac Rhythm Management Devices: World Market Outlook, 2011-2021, published in December 2011Visiongain, Press Release 07/12/2011
[2] PRLog Press Release, August 3, 2010 regarding: Neurostimulation Devices – Global Pipeline Analysis, Opportunity Assessment and Market Forecasts, Global Data, June 2010
To inquire more about how Signal Advance Technology, could benefit your industry or to discuss licensing and development options, please contact us. Continue to Industrial Market Analysis.